Yarrow Bioscience Inc - Asset Resilience Ratio
Yarrow Bioscience Inc (YARW) has an Asset Resilience Ratio of 1.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Yarrow Bioscience Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Yarrow Bioscience Inc's Asset Resilience Ratio has changed over time. See Yarrow Bioscience Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Yarrow Bioscience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Yarrow Bioscience Inc (YARW) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $297.00K | 1.15% |
| Total Liquid Assets | $297.00K | 1.15% |
Asset Resilience Insights
- Limited Liquidity: Yarrow Bioscience Inc maintains only 1.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yarrow Bioscience Inc Industry Peers by Asset Resilience Ratio
Compare Yarrow Bioscience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.85% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT |
Biotechnology | 41.14% |
|
Pharvaris BV
NASDAQ:PHVS |
Biotechnology | 0.06% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 29.87% |
Annual Asset Resilience Ratio for Yarrow Bioscience Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Yarrow Bioscience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.52% | $4.98 Million | $30.16 Million | -45.65pp |
| 2024-12-31 | 62.16% | $41.59 Million | $66.91 Million | -1.95pp |
| 2023-12-31 | 64.12% | $62.63 Million | $97.69 Million | +63.02pp |
| 2020-12-31 | 1.10% | $1.03 Million | $93.74 Million | -57.22pp |
| 2019-12-31 | 58.31% | $46.17 Million | $79.17 Million | -3.67pp |
| 2018-12-31 | 61.99% | $86.74 Million | $139.93 Million | -11.73pp |
| 2017-12-31 | 73.72% | $49.30 Million | $66.87 Million | +9.80pp |
| 2016-12-31 | 63.92% | $26.88 Million | $42.05 Million | -- |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more